Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hospira Will Not Be Reheard On Retacrit Biosimilar

Firm Had Petitioned Over Infringement And Damages Affirmation

Executive Summary

Hospira has been frustrated again in long-running litigation concerning its Retacrit biosimilar to Amgen’s Epogen, in a case closely watched by the biopharma industry as it addressed what constitutes a safe harbor for a biosimilar applicant.

You may also be interested in...



US Upholds $70m Hospira Epogen Verdict

Federal Circuit affirms jury's $70m award to Amgen and finding that some Hospira biosimilar batches were not protected by the safe harbor. Decision conveys how biosimilar makers can obtain this protection from infringement suits.

Cipla First On Generic Nexium Formulation

India’s Cipla has received the first US approval for a generic rival to Nexium delayed-release oral suspension in the US. The firm recently declared its intention to direct funds to more complex formulations in the US but nevertheless continues to grow its vast portfolio in the market.

Nivagen Raises Cash To Fuel Growth

California-based Nivagen is continuing to raise money to push through a number of generic launches in the US this year, the company’s founder and chief Jay Shukla told Generics Bulletin.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149733

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel